The biotech firm priced 18.3M shares above expectations, securing gross proceeds of $375.15M for pipeline development.
Dyne Therapeutics priced an upsized public offering of 18.3M common shares at $20.50 each, raising gross proceeds of $375.15M. The offering exceeds initial expectations, reflecting strong investor demand for the biotech firm’s pipeline.
Prior to the offering, Dyne’s shares traded at a lower valuation, with recent financing rounds indicating growing confidence in its therapeutic candidates. The proceeds will fund clinical trials and operational expansion.
Market reaction to the announcement was muted, with shares holding steady in after-hours trading.